Estrogen-Independent Proliferation Is Present in Estrogen-Receptor<i>HER2</i>-Positive Primary Breast Cancer After Neoadjuvant Letrozole

American Society of Clinical Oncology (ASCO) - Tập 24 Số 19 - Trang 3019-3025 - 2006
Matthew J. Ellis1, Yu Tao1, Oliver Young1, Sharon White1, Alan D. Proia1, Julliette Murray1, Lorna Renshaw1, Dana Faratian1, J. M. Thomas1, Mitch Dowsett1, Andreas Krause1, Dean B. Evans1, William R. Miller1, J. Michael Dixon1
1From the Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, MO; Duke University Medical Center, Durham, NC; Edinburgh Breast Unit, Edinburgh University, Edinburgh, Scotland; Royal Marsden Hospital, London, United Kingdom; and Novartis Pharma AG, Basel, Switzerland.

Tóm tắt

PurposeTo investigate the impact of human epidermal growth factor receptor (HER) 1 and HER2 gene amplification on endocrine therapy responsiveness, a fluorescence in situ hybridization (FISH) study was conducted on tumor samples from 305 postmenopausal patients with stage II and III estrogen receptor (ER) –positive (ER ≥ 10%) breast cancers treated on two independent neoadjuvant endocrine therapy trials.Patients and MethodsFISH analysis focused on HER1 and/or HER2 immunohistochemistry (IHC) -positive patients and a random selection of HER1/2 IHC-negative patients. HER2 FISH status was correlated with response and changes in the proliferation marker Ki67.ResultsHER1 was rarely amplified (< 1%), and HER2 amplification was observed in 9.2% of patients. Letrozole response by clinical measurement (71% HER2 FISH positive v 71% HER2 FISH negative), mammogram (44% HER2 FISH positive v 47% HER2 FISH negative), or ultrasound (47% HER2 FISH positive v 54% HER2 FISH negative) was not impaired by HER2 FISH-positive status. In contrast, HER2 FISH-positive tumors showed higher histologic grade (P = .009), higher pretreatment Ki67 (P = .005), and less Ki67 suppression after letrozole when compared with HER2 FISH-negative tumors (P = .0001). Similar observations regarding Ki67 were made in a smaller cohort of tamoxifen-treated tumors.ConclusionNeoadjuvant letrozole is clinically effective in ER-positive HER2 FISH-positive tumors, indicating sensitivity to short-term estrogen deprivation. However, continued proliferation despite ongoing letrozole or tamoxifen treatment in the majority of ER-positive HER2 FISH-positive samples (88%) could imply therapeutic resistance that may manifest later in the clinical course of the disease. Discordance between clinical and biomarker findings in this study serves to emphasize the need for surrogate end point validation in neoadjuvant endocrine trials through correlation with information on long-term outcomes.

Từ khóa


Tài liệu tham khảo

10.1053/ejso.2000.1078

10.1200/JCO.2000.18.20.3471

10.1200/JCO.2001.19.18.3808

10.1200/JCO.2005.04.005

10.1309/YMJ3A83TB39MRUT9

Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523,2003-6531,

Dowsett M, Smith IE, Ebbs SR: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951s,2005-958s,

10.1023/A:1013128213451

10.1007/BF02524791

10.1136/gut.50.3.373

10.1016/j.jsbmb.2005.04.017

Dowsett M, Harper-Wynne C, Boeddinghaus I, et al: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452,2001-8458,

10.1126/science.1104819

10.1016/S0303-7207(99)00003-9

Heer K, Kumar H, Read JR, et al: Serum vascular endothelial growth factor in breast cancer: Its relation with cancer type and estrogen receptor status. Clin Cancer Res 7:3491,2001-3494,

10.1200/JCO.2005.07.559

Turner J, Bentey R, Tao Y, et al: Changes in tumor grade with neoadjuvant endocrine therapy: Morphological evidence for fundamental differences in the anti-tumor effects of letrozole and tamoxifen. Breast Cancer Res Treat 88:S37,2004, (abstr 407)

10.1002/bjs.1800780228

10.1677/erc.1.00835

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 24 Số 19

3019-3025

Thông tin tác giả